Correlations of cancer pain degree with levels of β-EP, CGRP and PGE2 and the effects of oxycontin on them.
To analyze the eﬀects of Oxycontin on β-endorphin (β-EP), calcitonin gene-related peptide (CGRP) and prostaglandin E2 (PGE2) in treating patients with cancer pain, and to investigate and discuss the role and value of Oxycontin in treating cancer pain. A total of 95 patients (60 male and 35 female) were enrolled in the study, who were diagnosed in our hospital with malignant tumors complicated with pain from May 2016 to July 2017. All received Oxycontin for pain relief in addition to conventional treatment. The role of Oxycontin was analyzed by collecting the patients' general information, age, gender, Karnofsky performance status (KPS) score, site of pain and degree of pain, and by detecting the remission rates of clinical symptoms, average analgesic time, number of pain outbreak per day, levels of β-EP, CGRP and PGE2, as well as changes of KPS score, Zubrod performance status (ZPS) score and quality of life (QoL) score of the enrolled patients before treatment and at 1 week afer treatment. (1) Afer treatment with Oxycontin, the remission rate of clinical symptoms was signifcantly increased, the average analgesic time was extended remarkably and the number of pain outbreaks per day was decreased notably. All the diﬀerences were statistically signifcant (p<0.05). (2) For patients with cancer pain receiving Oxycontin, the main adverse reactions were nausea and vomiting (15.37%), followed by constipation, abdominal distension and anorexia. (3) At 1 week afer Oxycontin therapy, the KPS score and QoL score of the enrolled patients were increased, while the ZPS score was decreased, and the diﬀerences were statistically signifcant (p<0.05). (4) At 1 week afer treatment with Oxycontin, the levels of β-EP, CGRP and PGE2 of the enrolled patients were signifcantly lowered (p<0.05). (5) The levels of β-EP, CGRP and PGE2 with regard to the average analgesic time were negatively correlated with β-EP (r=-0.765, p<0.01), CGRP (r=-0.673, p<0.01) and PGE2 (r=-0.801, p<0.01). On treating patients with cancer pain, Oxycontin can signifcantly decrease the β-EP, CGRP and PGE2 levels, ameliorate the clinical symptoms, eﬀectively relieve the pain and improve the QoL to some extent.